ICON Past Earnings Performance
Past criteria checks 5/6
ICON has been growing earnings at an average annual rate of 19.1%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 26.1% per year. ICON's return on equity is 7.7%, and it has net margins of 9%.
Key information
19.1%
Earnings growth rate
5.7%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 26.1% |
| Return on equity | 7.7% |
| Net Margin | 9.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For
Nov 02
Here's Why ICON (NASDAQ:ICLR) Has Caught The Eye Of Investors
Sep 25Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Sep 09We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Aug 25An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued
Aug 10ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)
Jul 13Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)
Jun 14Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching
May 30ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 14ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 28What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump
Mar 05With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Feb 07ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?
Feb 01These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Jan 23Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jan 08What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E
Dec 24A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Dec 09With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Nov 08Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Oct 09Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Sep 23Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Sep 05Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Aug 03Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jun 30Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Jun 12Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
May 23Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Mar 29Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Mar 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?
Feb 21Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Dec 28These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Dec 10Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?
Nov 22Icon selected by BARDA to conduct anthrax vaccine clinical trial
Oct 06Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?
Sep 15ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly
Aug 26Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth
Aug 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?
Aug 01Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How ICON makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 8,307 | 748 | 777 | 0 |
| 30 Jun 24 | 8,332 | 714 | 758 | 0 |
| 31 Mar 24 | 8,232 | 683 | 754 | 0 |
| 31 Dec 23 | 8,120 | 612 | 776 | 0 |
| 30 Sep 23 | 8,016 | 513 | 811 | 0 |
| 30 Jun 23 | 7,903 | 510 | 790 | 0 |
| 31 Mar 23 | 7,818 | 510 | 790 | 0 |
| 31 Dec 22 | 7,741 | 505 | 783 | 0 |
| 30 Sep 22 | 7,665 | 464 | 758 | 0 |
| 30 Jun 22 | 7,588 | 210 | 871 | 0 |
| 31 Mar 22 | 6,524 | 168 | 771 | 0 |
| 31 Dec 21 | 5,481 | 153 | 662 | 0 |
| 30 Sep 21 | 4,356 | 178 | 547 | 0 |
| 30 Jun 21 | 3,191 | 364 | 350 | 0 |
| 31 Mar 21 | 2,940 | 338 | 344 | 0 |
| 31 Dec 20 | 2,797 | 328 | 342 | 0 |
| 30 Sep 20 | 2,762 | 322 | 343 | 0 |
| 30 Jun 20 | 2,771 | 324 | 345 | 0 |
| 31 Mar 20 | 2,846 | 368 | 344 | 0 |
| 31 Dec 19 | 2,806 | 369 | 333 | 0 |
| 30 Sep 19 | 2,759 | 362 | 336 | 0 |
| 30 Jun 19 | 2,704 | 353 | 330 | 0 |
| 31 Mar 19 | 2,651 | 333 | 328 | 0 |
| 31 Dec 18 | 2,596 | 323 | 326 | 0 |
| 30 Sep 18 | 2,372 | 306 | 321 | 0 |
| 30 Jun 18 | 2,157 | 295 | 320 | 0 |
| 31 Mar 18 | 1,947 | 288 | 326 | 0 |
| 31 Dec 17 | 1,758 | 281 | 324 | 0 |
| 30 Sep 17 | 1,738 | 285 | 331 | 0 |
| 30 Jun 17 | 1,718 | 274 | 333 | 0 |
| 31 Mar 17 | 1,698 | 271 | 326 | 0 |
| 31 Dec 16 | 1,666 | 262 | 326 | 0 |
| 30 Sep 16 | 1,635 | 251 | 326 | 0 |
| 30 Jun 16 | 1,609 | 249 | 327 | 0 |
| 31 Mar 16 | 1,587 | 247 | 328 | 0 |
| 31 Dec 15 | 1,575 | 240 | 327 | 0 |
| 30 Sep 15 | 1,562 | 221 | 329 | 0 |
| 30 Jun 15 | 1,555 | 210 | 331 | 0 |
| 31 Mar 15 | 1,542 | 192 | 337 | 0 |
| 31 Dec 14 | 1,503 | 172 | 336 | 0 |
| 30 Sep 14 | 1,458 | 161 | 330 | 0 |
| 30 Jun 14 | 1,411 | 138 | 327 | 0 |
| 31 Mar 14 | 1,369 | 120 | 317 | 0 |
| 31 Dec 13 | 1,336 | 103 | 314 | 0 |
Quality Earnings: ICLR has high quality earnings.
Growing Profit Margin: ICLR's current net profit margins (9%) are higher than last year (6.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ICLR's earnings have grown by 19.1% per year over the past 5 years.
Accelerating Growth: ICLR's earnings growth over the past year (45.7%) exceeds its 5-year average (19.1% per year).
Earnings vs Industry: ICLR earnings growth over the past year (45.7%) exceeded the Life Sciences industry -4.7%.
Return on Equity
High ROE: ICLR's Return on Equity (7.7%) is considered low.